文献速递肝病消化道肿瘤与早癌

《平价医疗法案》改善肝病患者的可及性、生存率及种族差异:一项系统综述

The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-07

本系统综述纳入2010至2025年发表的27项研究,评估《平价医疗法案》(ACA)及其医疗补助扩展(ME)条款对慢性肝病成人患者服务可及性、生存或死亡及种族差异的影响。23项研究报告ACA/ME与结局改善相关,差异中的差异分析显示ME州肝移植等待名单增加1.8%至6.0%、早期肝细胞癌诊断增加5.4%,肝硬化相关死亡率上升更慢。结论认为ACA尤其ME改善了医疗补助合格慢性肝病成人的可及性、生存与公平性。

要点

  • 27项研究中23项报告ACA/ME与慢性肝病患者的结局改善相关。
  • 差异中的差异分析显示ME州肝移植等待名单增加1.8%至6.0%。
  • ME州早期肝细胞癌诊断增加5.4%,肝硬化相关死亡率上升更慢。

核心结论

  • ACA尤其ME改善了医疗补助合格的慢性肝病成人的可及性、生存与公平性。
  • 作者认为未扩展医疗补助州的个体可能从扩展中获益。
  • 作者认为未来肝脏健康政策应考虑这些发现以减少差异。

研究设计与样本

  • 系统综述,检索2010年至2025年发表的研究。
  • 纳入对象为患有慢性肝病的成人。
  • 纳入评估ACA/ME对服务可及性、生存或死亡或结局差异影响的研究。
  • 比较医疗补助扩展州与未扩展州在ACA实施前后的时期。
  • 共纳入27项研究,覆盖丙型肝炎病毒(n=4)、肝移植(n=10)、肝细胞癌(n=9)及肝硬化或慢性肝病(n=5)四类临床领域。

主要发现

  • 23项研究报告ACA/ME与结局改善相关。
  • 差异中的差异分析显示,医疗补助扩展州较未扩展州肝移植等待名单增加1.8%至6.0%。
  • 差异中的差异分析显示早期肝细胞癌诊断增加5.4%。
  • 医疗补助扩展州肝硬化相关死亡率上升更慢(每10万人0.5至1.0 vs 每10万人1.4至10.4)。
  • 多数研究为低至中等偏倚风险,并使用了因果推断方法。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Given the evolving epidemiology of liver disease, escalating healthcare costs, and persistent racial health disparities, evaluating the Affordable Care Act (ACA)-the most substantial U.S. healthcare reform to date-is critical for informing future policy. We conducted a systematic review to assess the impact of the ACA and its Medicaid Expansion (ME) provision on access to care, survival, and racial and ethnic disparities among patients with chronic liver disease (CLD). METHODS: We reviewed studies published between 2010 and 2025 that included adults with CLD and evaluated ACA/ME effects on access to services, survival or mortality, or disparities in outcomes. Studies compared ME and non-Medicaid Expansion (NME) states during pre- and post-ACA periods. Risk of bias was assessed using a validated tool. RESULTS: Twenty-seven studies met inclusion criteria across 4 clinical categories: hepatitis C virus (n = 4), liver transplantation (n = 10), hepatocellular carcinoma (n = 9), and cirrhosis or CLD (n = 5). Twenty-three studies reported improved outcomes associated with ACA/ME. Difference-in-difference analyses showed liver transplantation listing increased by 1.8% to 6.0% in ME vs NME states; early-stage hepatocellular carcinoma diagnosis increased by 5.4%, and cirrhosis-related mortality rose more slowly in ME states (0.5-1.0 per 100,000 vs 1.4-10.4 per 100,000). Most studies were at low-to-moderate risk of bias and used causal inference methods. CONCLUSIONS: The ACA, particularly ME, improved access, survival, and equity among Medicaid-eligible adults with CLD. Individuals in NME states would likely benefit from expansion, and future liver health policy should consider these findings to reduce disparities.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Walker TL, Aridi TG, Iyengar M, et al. The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2025. PMID: 40633891. doi:10.1016/j.cgh.2025.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。